Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.
The feat, reported in the scientific journal Nature Biotechnology, offers gene therapy designers what may be the first viable technique for adjusting the activity levels of their therapeutic genes. The lack of such a basic safety feature has limited the development of gene therapy, which otherwise holds promise for addressing genetically based conditions. The scientists’ technique appears to solve a major safety issue and may lead to more use of the strategy.
The Scripps Research team, led by principal investigator Michael Farzan, PhD, demonstrated the power of their new switching technique by incorporating it into a gene therapy that produces the hormone erythropoietin, used as a treatment for anemia. They showed that they could suppress expression of its gene to very low levels with a special embedded molecule, and could then increase the gene’s expression, over a wide dynamic range, using injected control molecules called morpholinos that the U.S. Food and Drug Administration has found to be safe for other applications.
“I think that our approach offers the only practical way at present to regulate the dose of a gene therapy in an animal or a human,” Farzan says.
Gene therapies work by inserting copies of a therapeutic gene into the cells of a patient, if, for example, the patient was born without functional copies of the needed gene. The strategy has long been seen as having enormous potential to cure diseases caused by defective genes. It also could enable patients to receive a steady, long-term delivery of therapeutic molecules that are impractical to deliver in pills or injections because they don’t survive for long in the body.
However, gene therapies have been viewed as inherently risky because once they are delivered to a patient’s cells, they cannot be switched off or modulated. As a result, only a handful of gene therapies have been FDA-approved to date.
The simplicity of the technique, and the fact that morpholinos are already FDA-approved, could allow the new transgene switching system to be used in a wide variety of envisioned gene therapies, Farzan adds.
Farzan’s team, including study co-first authors Guocai Zhong, PhD and Haimin Wang, respectively a postdoctoral researcher and a research assistant in the Farzan lab, crafted a transgene switch from a family of ribonucleic acid (RNA) molecules called hammerhead ribozymes. These ribozymes have the remarkable property that they cut themselves in two as soon as they are copied out into RNA from the DNA that encodes them.
A therapeutic transgene containing the DNA of such a ribozyme will thus be copied out in cells into strands of RNA, called transcripts, that will tend to separate into two pieces before they can be translated into proteins. However, this self-cleaving action of the ribozyme can be blocked by RNA-like morpholinos that latch onto the ribozyme’s active site; if this happens, the transgene transcript will remain intact and will be more likely to be translated into the therapeutic protein.
The ribozyme thus effectively acts as an “off switch” for the transgene, whereas the matching morpholinos, injected into the tissue where the transgene resides, can effectively turn the transgene back “on” again—to a degree that depends on the morpholino dose.
The scientists started with a hammerhead ribozyme called N107 that had been used as an RNA switch in prior studies, but they found that the difference in production of a transgene-encoded test protein between the “off” and “on” state was too modest for this ribozyme to be useful in gene therapies. However, over months of experimentation they were able to modify the ribozyme until it had a dynamic range that was dozens of times wider.
The team then demonstrated the ribozyme-based switch in a mouse model of an EPO gene therapy, which isn’t yet FDA-approved but is considered potentially better than current methods for treating anemia associated with severe kidney disease. They injected an EPO transgene into muscle tissue in live mice, and showed that the embedded ribozyme suppressed EPO production to a very low level.
Injection of a small dose of the morpholino molecules into affected tissue strongly reversed that suppression, allowing EPO production to rise by a factor of more than 200—and stay there for more than a week, compared to a half-life of a few hours for EPO delivered by a standard injection. Those properties make the ribozyme-based switch potentially suitable for real clinical applications.
“We got what I would have said before was an impossible range of in vivo regulation from this system,” Farzan says.
Farzan and his colleagues are now working to adapt their ribozyme switch technique so that it can be used as a gene therapy failsafe mechanism, deactivating errant transgenes permanently.
Learn more: New technology allows control of gene therapy doses
Go deeper with Bing News on:
Gene therapies
- More children gain hearing as gene therapy for profound deafness advances
Enlarge / Opal Sandy (center), who was born completely deaf because of a rare genetic condition, can now hear unaided for the first time after receiving gene therapy at 11-months-old. She is shown ...
- Gene Therapy Trial Restores Hearing in Baby Girl
A gene therapy trial at Cambridge University Hospitals in the UK has improved the hearing of an 18-month-old baby girl, born deaf due to auditory neuropathy.
- Toddler born deaf can hear after gene therapy trial breakthrough her parents call "mind-blowing"
The parents of a U.K. toddler say it's "absolutely mind-blowing" to see their daughter, enrolled in a gene therapy trial, hear for the first time.
- Gene therapy brings hearing to baby girl born deaf
Opal Sandy was born into a world she could not hear. The British baby girl, now 18 months old, had a rare genetic condition called auditory neuropathy that interrupted nerve impulses that travel from ...
- Child who was born deaf can now hear whispers and parents clapping for first time thanks to ‘mind-blowing’ gene therapy
A deaf child has received a new gene therapy treatment with “mind-blowing” results that have allowed her to hear for the first time. Opal Sandy, from Oxfordshire, UK, is the first British patient and ...
Go deeper with Google Headlines on:
Gene therapies
[google_news title=”” keyword=”gene therapies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Molecular switch
- Nobel laureate shares vision for molecular machines at Fudan University
Bernard Lucas Feringa, the 2016 Nobel laureate in chemistry, presented his pioneering work constructing molecular machines that operate on tiny scales at a lecture at Fudan University on Friday, ...
- New sex-determining mechanism in African butterfly discovered
Across species, a molecular switch is required to initiate development of a newly formed embryo into a female or a male. The genetic identity of this molecular switch, and how it actually works, ...
- Researchers discover new function of oncoproteins
Researchers at the University of Würzburg have discovered a new function of the oncoprotein MYCN: It not only helps cancer cells to grow stronger, but also makes them more resistant to drugs. The ...
- Study reveals flaw in long-accepted approximation used in water simulations
Computational scientists at the Department of Energy's Oak Ridge National Laboratory have published a study in the Journal of Chemical Theory and Computation that questions a long-accepted factor in ...
- Could cannabis treat cancer someday? Here's what the science says so far
For example, in rodent studies, cannabinoids have been shown to inhibit cancer cell growth by flipping specific molecular switches in tumor cells. And in cell studies, cannabinoids have damaged tumors ...
Go deeper with Google Headlines on:
Molecular switch
[google_news title=”” keyword=”molecular switch” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]